|Bid||0.00 x 1100|
|Ask||0.00 x 1800|
|Day's Range||15.48 - 15.74|
|52 Week Range||12.68 - 22.49|
|Beta (3Y Monthly)||-0.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
Codexis, Inc. (CDXS), a leading protein engineering company, announces the publication with Merck, known as MSD outside the United States and Canada, of a paper in the prestigious peer-reviewed journal Science, detailing the development of a novel, highly efficient enzymatic cascade for the production of Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The publication (https://science.sciencemag.org/content/366/6470/1255) describes the optimization, using Codexis’ proprietary CodeEvolver® protein engineering platform, of five enzymes for the synchronized synthesis of a complex pharmaceutical candidate in very few steps, starting from simple raw materials. Merck and Codexis collaborated on the engineering of the enzymes to enable the efficient synthesis of the Active Pharmaceutical Ingredient (API).
For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality...
Codexis (CDXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Codexis (CDXS) delivered earnings and revenue surprises of 166.67% and 32.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Total revenues rose 29% to $21.9 million driven by strength in R&D, product, and CodeEvolver® licensing revenues Eleven customers each contributed at least a quarter.
REDWOOD CITY, Calif., Nov. 05, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in four upcoming.
REDWOOD CITY, Calif., Oct. 29, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report third quarter 2019 financial results.
How do we determine whether Codexis, Inc. (NASDAQ:CDXS) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
Codexis, Inc. (CDXS), a leading protein engineering company, assembled approximately 150 top scientists in protein engineering to discuss recent progress and future direction in a forum held last week in Palo Alto, Calif. Speakers highlighted recent successes in enzymatic manufacturing, biologics discovery, and agricultural and diagnostic applications, as well as technical progress in library generation, high-throughput screening, and bioinformatics. The keynote address by Nobel Laureate Dr. Frances H. Arnold illuminated the audience on the history of the field and highlighted the promise of protein engineering technology.
REDWOOD CITY, Calif., Sept. 26, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor.
President and CEO of Codexis Inc (30-Year Financial, Insider Trades) John J Nicols (insider trades) bought 10,000 shares of CDXS on 08/20/2019 at an average price of $13.3 a share. Continue reading...
Codexis (CDXS) delivered earnings and revenue surprises of -100.00% and -17.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Product revenue up 68%; R&D revenue spread over wider base of customers and markets Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif., Aug. 06,.
REDWOOD CITY, Calif., July 30, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2019 financial results.
Codexis, Inc. (CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement. “The value and the versatility of Codexis’ business and engineering platform enables a diverse set of high-growth capabilities across multiple markets,” said Codexis President and CEO John Nicols.